

Bassel F El-Rayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3670026/publications.pdf>

Version: 2024-02-01

370
papers

11,760
citations

23544

58
h-index

39638

94
g-index

379
all docs

379
docs citations

379
times ranked

16675
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564. | 3.4 | 746 |
| 2 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810. | 5.1 | 719 |
| 3 | Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2015, 35, S224-S243. | 4.3 | 375 |
| 4 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171. | 2.9 | 279 |
| 5 | Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 1357-1370. | 0.8 | 278 |
| 6 | Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818. | 2.9 | 232 |
| 7 | Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794. | 3.0 | 223 |
| 8 | Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304. | 4.3 | 220 |
| 9 | Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4012-4012. | 0.8 | 178 |
| 10 | Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2013, 42, 1311-1315. | 0.5 | 166 |
| 11 | Targeting the epidermal growth factor receptor. <i>British Journal of Cancer</i> , 2004, 91, 418-424. | 2.9 | 151 |
| 12 | First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United Statesâ€Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118. | 0.8 | 144 |
| 13 | Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 440-448. | 0.9 | 133 |
| 14 | Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116. | 1.9 | 131 |
| 15 | Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-Î². <i>Cancer Research</i> , 2006, 66, 10553-10559. | 0.4 | 127 |
| 16 | CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609. | 1.8 | 127 |
| 17 | The prognostic and predictive impact of inflammatory biomarkers in patients who have advancedâ€stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134. | 2.0 | 120 |
| 18 | Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. <i>Carcinogenesis</i> , 2014, 35, 967-973. | 1.3 | 115 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , 2016, 24, 1150-1158. | 3.7 | 114 |
| 20 | Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF- κ B in BxPC-3 Pancreatic Cancer Cell Line. <i>Pancreas</i> , 2004, 28, e90-e95. | 0.5 | 111 |
| 21 | mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). <i>Annals of Oncology</i> , 2013, 24, 965-973. | 0.6 | 109 |
| 22 | Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: \leq 2, pT2: $>$ 2 \leq 4, pT3: $>$ 4 cm) is More Valid and Clinically Relevant. <i>Annals of Surgical Oncology</i> , 2016, 23, 2010-2018. | 0.7 | 107 |
| 23 | Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003, 61, 774-780. | 0.5 | 106 |
| 24 | Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. <i>Cancer</i> , 2013, 119, 3148-3155. | 2.0 | 105 |
| 25 | Carbohydrate antigen 19 \leq 9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. <i>Cancer</i> , 2013, 119, 285-292. | 2.0 | 103 |
| 26 | Exploitation of protein kinase C: A useful target for cancer therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 1-8. | 3.4 | 101 |
| 27 | Hypoxia inducible factor-1 α : Its role in colorectal carcinogenesis and metastasis. <i>Cancer Letters</i> , 2015, 366, 11-18. | 3.2 | 96 |
| 28 | Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. <i>Annals of Surgical Oncology</i> , 2015, 22, 2295-2301. | 0.7 | 93 |
| 29 | The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2166. | 2.2 | 92 |
| 30 | Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. <i>Cancer</i> , 2017, 123, 345-356. | 2.0 | 91 |
| 31 | A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. <i>Annals of Oncology</i> , 2010, 21, 1999-2004. | 0.6 | 89 |
| 32 | Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , 2017, 123, 1303-1312. | 2.0 | 89 |
| 33 | Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 494-503. | 2.1 | 88 |
| 34 | Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857. | 1.1 | 88 |
| 35 | Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 256-265. | 0.2 | 86 |
| 36 | Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732. | 0.8 | 86 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2005, 23, 583-590. | 1.2 | 85 |
| 38 | Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane <i>in vitro</i> and <i>in vivo</i> using an orthotopic model of pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1708-1719. | 1.9 | 82 |
| 39 | Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. <i>Molecular Cancer</i> , 2018, 17, 177. | 7.9 | 80 |
| 40 | Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 327-327. | 0.8 | 80 |
| 41 | Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging. <i>Annals of Surgical Oncology</i> , 2015, 22, 1187-1195. | 0.7 | 79 |
| 42 | Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, 1147-1158. | 1.3 | 78 |
| 43 | A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 117, 1592-1599. | 2.9 | 77 |
| 44 | Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461. | 1.9 | 75 |
| 45 | The impact of curcumin on breast cancer. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 996-1007. | 0.6 | 74 |
| 46 | Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. <i>Cancer Letters</i> , 2013, 341, 195-203. | 3.2 | 73 |
| 47 | Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 α and STAT-3. <i>Angiogenesis</i> , 2013, 16, 903-917. | 3.7 | 72 |
| 48 | Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. <i>Cancer Letters</i> , 2015, 357, 557-565. | 3.2 | 71 |
| 49 | Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group/American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017, 35, 718-726. | 0.8 | 70 |
| 50 | Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 307-315. | 0.2 | 68 |
| 51 | Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. <i>Nutrition Reviews</i> , 2013, 71, 562-572. | 2.6 | 68 |
| 52 | Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC. <i>American Journal of Roentgenology</i> , 2014, 203, W706-W714. | 1.0 | 66 |
| 53 | Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1943-1951. | 1.9 | 65 |
| 54 | Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. <i>Journal of Surgical Oncology</i> , 2015, 111, 1028-1034. | 0.8 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582. | 2.0 | 65 |
| 56 | Epigenetics in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2022, 86, 622-632. | 4.3 | 64 |
| 57 | Inhibition of NF- κ B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , 2016, 373, 227-233. | 3.2 | 63 |
| 58 | Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 143-151. | 0.6 | 62 |
| 59 | A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 296-303. | 0.4 | 61 |
| 60 | Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. <i>Modern Pathology</i> , 2016, 29, 1575-1585. | 2.9 | 56 |
| 61 | In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 469-476. | 0.4 | 55 |
| 62 | Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 299-315. | 1.2 | 55 |
| 63 | Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. <i>Modern Pathology</i> , 2016, 29, 1243-1253. | 2.9 | 53 |
| 64 | A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3541-3541. | 0.8 | 53 |
| 65 | A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011, 29, 694-699. | 1.2 | 52 |
| 66 | HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. <i>Oncotarget</i> , 2014, 5, 9980-9991. | 0.8 | 52 |
| 67 | Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174. | 2.0 | 51 |
| 68 | Combination of Tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. <i>Oncotarget</i> , 2016, 7, 3186-3200. | 0.8 | 50 |
| 69 | Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2920-2925. | 0.8 | 49 |
| 70 | Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187. | 1.9 | 47 |
| 71 | A phase II study of carboplatin and paclitaxel in esophageal cancer. <i>Annals of Oncology</i> , 2004, 15, 960-965. | 0.6 | 46 |
| 72 | Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , 2019, 145, 1529-1537. | 2.3 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Aquaporins: Their role in gastrointestinal malignancies. <i>Cancer Letters</i> , 2016, 373, 12-18. | 3.2 | 45 |
| 74 | Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573. | 0.6 | 45 |
| 75 | Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 308-18. | 0.6 | 45 |
| 76 | Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535. | 1.9 | 44 |
| 77 | An analysis of human equilibrative nucleoside transporter 1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene 1 expression in patients with resected pancreas adenocarcinoma. <i>Cancer</i> , 2013, 119, 445-453. | 2.0 | 42 |
| 78 | Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF- κ B translocation to nucleus and cell cycle phase distribution. <i>Journal of Nutritional Biochemistry</i> , 2016, 31, 77-87. | 1.9 | 42 |
| 79 | Targeting KRAS in pancreatic cancer: new drugs on the horizon. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 819-835. | 2.7 | 41 |
| 80 | Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. <i>Annals of Surgical Oncology</i> , 2011, 18, 2699-2705. | 0.7 | 39 |
| 81 | Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 416-426. | 2.0 | 39 |
| 82 | High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920. | 1.9 | 39 |
| 83 | Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , 2016, 52, 109-119. | 1.3 | 38 |
| 84 | Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269. | 0.8 | 37 |
| 85 | Non-ampullary "duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 255-266. | 2.9 | 36 |
| 86 | Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 74-81. | 0.6 | 36 |
| 87 | CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 98-105. | 0.7 | 35 |
| 88 | Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225. | 1.0 | 35 |
| 89 | High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 631-639. | 0.4 | 35 |
| 90 | Treatment allocation in patients with early stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. <i>Cancer</i> , 2016, 122, 2150-2157. | 2.0 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. <i>International Journal of Oncology</i> , 2016, 48, 1955-1964. | 1.4 | 35 |
| 92 | Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 288-299. | 1.3 | 35 |
| 93 | Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 3476-3485. | 2.0 | 35 |
| 94 | CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. <i>Cancer Research</i> , 2014, 74, 2677-2687. | 0.4 | 34 |
| 95 | Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated $\text{I}\pm\text{-Gd}^{2+}$ (MoO_4) $^{3-}$ mesoporous particles. <i>Dalton Transactions</i> , 2014, 43, 3330-3338. | 1.6 | 34 |
| 96 | Correlates of financial toxicity in adult cancer patients and their informal caregivers. <i>Supportive Care in Cancer</i> , 2022, 30, 217-225. | 1.0 | 34 |
| 97 | Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. <i>International Journal of Cancer</i> , 2019, 145, 10-19. | 2.3 | 33 |
| 98 | Targeted therapies in metastatic esophageal cancer: Advances over the past decade. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 186-196. | 2.0 | 32 |
| 99 | Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 4392-4401. | 0.7 | 31 |
| 100 | Cyclooxygenase-2 in gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1221-1227. | 2.0 | 31 |
| 101 | Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 1-8. | 0.6 | 31 |
| 102 | Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. <i>JCI Insight</i> , 2020, 5, . | 2.3 | 31 |
| 103 | Developments in the Systemic Therapy of Pancreatic Cancer. <i>Cancer Investigation</i> , 2003, 21, 73-86. | 0.6 | 30 |
| 104 | HER2 in resected gastric cancer: Is there prognostic value?. <i>Journal of Surgical Oncology</i> , 2014, 109, 61-66. | 0.8 | 30 |
| 105 | Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 150-160. | 1.9 | 30 |
| 106 | Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604. | 1.3 | 30 |
| 107 | PEGylated $\text{I}\pm\text{-Gd}^{2+}$ (MoO_4) $^{3-}$ Mesoporous Flowers: Synthesis, Characterization, and Biological Application. <i>Crystal Growth and Design</i> , 2013, 13, 4051-4058. | 1.4 | 29 |
| 108 | Locoregional therapies for metastatic colorectal carcinoma to the liver-An evidence-based review. <i>Journal of Surgical Oncology</i> , 2014, 110, 182-196. | 0.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 1749-1757. | 0.8 | 29 |
| 110 | Excision repair cross-complementing gene 1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter 1 expression and prognostic value in biliary tract malignancy. <i>Cancer</i> , 2013, 119, 454-462. | 2.0 | 28 |
| 111 | SPARC and DNA methylation: Possible diagnostic and therapeutic implications in gastrointestinal cancers. <i>Cancer Letters</i> , 2013, 328, 10-17. | 3.2 | 28 |
| 112 | Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. <i>FASEB Journal</i> , 2019, 33, 3623-3635. | 0.2 | 28 |
| 113 | Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. <i>Endocrine Pathology</i> , 2020, 31, 239-253. | 5.2 | 28 |
| 114 | Protein Kinase C. <i>Pancreas</i> , 2008, 36, 346-352. | 0.5 | 27 |
| 115 | TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545. | 0.5 | 27 |
| 116 | Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. <i>World Journal of Gastroenterology</i> , 2020, 26, 4036-4054. | 1.4 | 27 |
| 117 | Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 111-116. | 1.1 | 26 |
| 118 | Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1286-1293.e1. | 0.2 | 26 |
| 119 | Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. <i>Cancer</i> , 2015, 121, 1772-1778. | 2.0 | 26 |
| 120 | Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2015, 20, 981-982. | 1.9 | 26 |
| 121 | Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. <i>International Journal of Oncology</i> , 2016, 49, 1686-1694. | 1.4 | 26 |
| 122 | Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618. | 0.8 | 26 |
| 123 | Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , 2015, 20, 907-914. | 1.9 | 25 |
| 124 | A Phase II Study of Carboplatin and Paclitaxel in Adenocarcinoma of Unknown Primary. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 152-156. | 0.6 | 24 |
| 125 | A phase I study of flavopiridol and docetaxel. <i>Investigational New Drugs</i> , 2006, 24, 305-310. | 1.2 | 24 |
| 126 | A Phase II Study of Preoperative Capecitabine and Radiation Therapy in Patients With Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 340-345. | 0.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Concurrent inhibition of NF- κ B, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 171-181. | 1.2 | 24 |
| 128 | Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94. | 0.6 | 24 |
| 129 | Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268. | 1.0 | 24 |
| 130 | ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4017-4017. | 0.8 | 24 |
| 131 | Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126. | 2.0 | 23 |
| 132 | Phase I Study of Bryostatin 1 and Gemcitabine. <i>Clinical Cancer Research</i> , 2006, 12, 7059-7062. | 3.2 | 22 |
| 133 | A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , 2013, 108, 762-765. | 2.9 | 22 |
| 134 | PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 1902. | 1.7 | 22 |
| 135 | Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 3384-90. | 0.7 | 21 |
| 136 | Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States. <i>Cancer</i> , 2013, 119, 4020-4027. | 2.0 | 20 |
| 137 | Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 543-549. | 0.6 | 20 |
| 138 | Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48. | 1.2 | 20 |
| 139 | Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. <i>Cancer</i> , 2017, 123, 4924-4933. | 2.0 | 20 |
| 140 | Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675. | 1.9 | 20 |
| 141 | Genomic alterations in appendiceal carcinoma using circulating DNA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 658-658. | 0.8 | 20 |
| 142 | Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 3242-3250. | 2.0 | 19 |
| 143 | Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. <i>Cancer Letters</i> , 2017, 402, 110-116. | 3.2 | 19 |
| 144 | National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746. | 2.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreaticobiliary origin.. Journal of Clinical Oncology, 2016, 34, 460-460. | 0.8 | 19 |
| 146 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 283-289. | 1.1 | 18 |
| 147 | Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, Publish Ahead of Print, 135-9. | 0.6 | 18 |
| 148 | Impact of Race, Age, and Socioeconomic Status on Participation in Pancreatic Cancer Clinical Trials. Pancreas, 2010, 39, 967-971. | 0.5 | 18 |
| 149 | Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1167-1174. | 1.4 | 18 |
| 150 | Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic Advances in Medical Oncology, 2015, 7, 56-62. | 1.4 | 18 |
| 151 | Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 659-670. | 1.1 | 18 |
| 152 | Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. , 2020, 8, e001100. | | 18 |
| 153 | Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. Cancer, 2020, 126, 3360-3371. | 2.0 | 18 |
| 154 | Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Research and Treatment, 2005, 90, 25-31. | 1.1 | 17 |
| 155 | Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707. | 3.0 | 17 |
| 156 | Oxaliplatin-Induced Hepatoportal Sclerosis, Portal Hypertension, and Variceal Bleeding Successfully Treated With Transjugular Intrahepatic Portosystemic Shunt. Clinical Colorectal Cancer, 2012, 11, 224-227. | 1.0 | 17 |
| 157 | Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer, 2018, 124, 1992-2000. | 2.0 | 17 |
| 158 | Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treatment Reviews, 2016, 42, 10-17. | 3.4 | 16 |
| 159 | Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2018, 126, 201-207. | 2.0 | 16 |
| 160 | Nonsurgical Management of Rectal Cancer. Journal of Oncology Practice, 2019, 15, 123-131. | 2.5 | 16 |
| 161 | A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy, 2021, 70, 3337-3348. | 2.0 | 16 |
| 162 | The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine. Oncology Reports, 2015, 34, 3304-3310. | 1.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 163 | Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711. | 1.9 | 15 |
| 164 | Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. <i>Annals of Surgical Oncology</i> , 2018, 25, 290-298. | 0.7 | 15 |
| 165 | <p>Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129. | 1.8 | 15 |
| 166 | Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67. | 2.0 | 15 |
| 167 | Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , 2020, 16, 319-325. | 1.4 | 15 |
| 168 | A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511. | 1.1 | 14 |
| 169 | Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , 2020, 126, 4788-4799. | 2.0 | 14 |
| 170 | PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1836-1845. | 1.9 | 14 |
| 171 | Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis. , 2012, , . | | 14 |
| 172 | Protein kinases C isozymes are differentially expressed in human breast carcinomas. <i>Life Sciences</i> , 2009, 84, 766-771. | 2.0 | 13 |
| 173 | Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. <i>Oncology</i> , 2017, 93, 336-342. | 0.9 | 13 |
| 174 | In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 660-667. | 0.5 | 13 |
| 175 | A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4106-4106. | 0.8 | 13 |
| 176 | Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861. | 1.4 | 13 |
| 177 | Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4412-4416. | 3.2 | 12 |
| 178 | Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 556-560. | 0.8 | 12 |
| 179 | Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. <i>Oncology</i> , 2019, 97, 49-58. | 0.9 | 12 |
| 180 | Young Adults With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 341-354. | 0.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 181 | MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers. <i>Tumor Biology</i> , 2016, 37, 97-104. | 0.8 | 11 |
| 182 | Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 944-956. | 0.6 | 11 |
| 183 | Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206. | 1.2 | 11 |
| 184 | Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. <i>Cancer</i> , 2020, 126, 37-45. | 2.0 | 11 |
| 185 | Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020, 25, 414-421. | 1.9 | 11 |
| 186 | Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 593-593. | 0.8 | 11 |
| 187 | Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4110-4110. | 0.8 | 11 |
| 188 | Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. <i>Investigational New Drugs</i> , 2005, 23, 57-62. | 1.2 | 10 |
| 189 | Biomarkers for personalized medicine in GI cancers. <i>Molecular Aspects of Medicine</i> , 2015, 45, 14-27. | 2.7 | 10 |
| 190 | Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , 2020, 22, 1675-1685. | 0.1 | 10 |
| 191 | Epidemiology of early esophageal adenocarcinoma. <i>Clinical Endoscopy</i> , 2022, 55, 372-380. | 0.6 | 10 |
| 192 | Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. <i>Frontiers in Oncology</i> , 2021, 11, 728076. | 1.3 | 10 |
| 193 | Tumor Angiogenesis Therapy Using Targeted Delivery of Paclitaxel to the Vasculature of Breast Cancer Metastases. <i>Journal of Drug Delivery</i> , 2014, 2014, 1-12. | 2.5 | 9 |
| 194 | Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 682-690. | 1.2 | 9 |
| 195 | Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1026-1033. | 0.7 | 9 |
| 196 | A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505. | 3.2 | 9 |
| 197 | Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , 2021, 11, 592351. | 1.3 | 9 |
| 198 | BBI608-503-103HCC: A phase 1b/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4077-4077. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 199 | Clinicopathological analysis of primary epithelial appendiceal neoplasms. <i>Medical Oncology</i> , 2010, 27, 1073-1078. | 1.2 | 8 |
| 200 | 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 435-444. | 0.6 | 8 |
| 201 | Chemotherapeutic Strategies in Advanced or Metastatic Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 194-200. | 0.6 | 8 |
| 202 | Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. <i>Cancer Medicine</i> , 2015, 4, 392-403. | 1.3 | 8 |
| 203 | Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. <i>Journal of Surgical Oncology</i> , 2016, 114, 336-341. | 0.8 | 8 |
| 204 | Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2020, 121, 294-302. | 0.8 | 8 |
| 205 | Visualizing cancer and response to therapy <i>in vivo</i> using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. <i>Journal of Drug Targeting</i> , 2015, 23, 257-265. | 2.1 | 7 |
| 206 | Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146. | 0.9 | 7 |
| 207 | Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919. | 0.5 | 7 |
| 208 | Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , 2021, 36, 120-129. | 0.8 | 7 |
| 209 | High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 755113. | 1.3 | 7 |
| 210 | Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy. <i>American Journal of Hematology</i> , 2003, 72, 154-154. | 2.0 | 6 |
| 211 | Cellular DNA content parameters as prognostic indicators in human astrocytomas. <i>Journal of Neuro-Oncology</i> , 2005, 71, 85-89. | 1.4 | 6 |
| 212 | Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 269-275. | 0.6 | 6 |
| 213 | Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , 2020, 126, 4136-4147. | 2.0 | 6 |
| 214 | Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234. | 2.9 | 6 |
| 215 | Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 97-105. | 0.7 | 6 |
| 216 | Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. <i>Anticancer Research</i> , 2012, 32, 3559-63. | 0.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 217 | Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 707-718. | 1.5 | 5 |
| 218 | An update on the multimodality of localized rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 23-32. | 2.0 | 5 |
| 219 | Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 331-336. | 0.6 | 5 |
| 220 | STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1138-1148. | 0.9 | 5 |
| 221 | Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1632. | 1.3 | 5 |
| 222 | Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 95-95. | 0.8 | 5 |
| 223 | Abstract 3119: A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer. <i>Cancer Research</i> , 2012, 72, 3119-3119. | 0.4 | 5 |
| 224 | Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3596-3596. | 0.8 | 5 |
| 225 | Long -Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. <i>Clinical Endoscopy</i> , 2017, 50, 491-494. | 0.6 | 5 |
| 226 | Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncology</i> , 2022, 100, 131-139. | 0.9 | 5 |
| 227 | Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. <i>Oncology Research and Treatment</i> , 2022, 45, 430-437. | 0.8 | 5 |
| 228 | Mo1135 Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States. <i>Gastroenterology</i> , 2014, 146, S-566-S-567. | 0.6 | 4 |
| 229 | Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 807-814. | 1.7 | 4 |
| 230 | FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , 2019, 70, e619. | 1.8 | 4 |
| 231 | Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020, 123, 1377-1386. | 2.9 | 4 |
| 232 | Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 239-244. | 0.3 | 4 |
| 233 | Comparison of DNA Content Parameters in Paired, Fresh Tissue Pretreatment Biopsies and Surgical Resections from Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2003, 128, 169-177. | 1.1 | 3 |
| 234 | Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study. <i>PLoS ONE</i> , 2017, 12, e0177212. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 235 | Interaction of heat shock protein 90 with hypoxia inducible factor and signal transducer and activator of transcription in colon cancer. <i>Process Biochemistry</i> , 2019, 86, 151-158. | 1.8 | 3 |
| 236 | Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , 2021, 123, 596-605. | 0.8 | 3 |
| 237 | Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 153-160. | 1.0 | 3 |
| 238 | Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G14-198).. <i>Journal of Clinical Oncology</i> , 2021, 39, 413-413. | 0.8 | 3 |
| 239 | Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 608-608. | 0.8 | 3 |
| 240 | Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3564-3564. | 0.8 | 3 |
| 241 | Phase 1b trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS526-TPS526. | 0.8 | 3 |
| 242 | A phase 1b study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284. | 0.8 | 3 |
| 243 | Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature. <i>Chinese Clinical Oncology</i> , 2022, 11, 8-8. | 0.4 | 3 |
| 244 | Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4336-4345. | 3.2 | 3 |
| 245 | A patient-centered team approach in oncology. <i>Cancer</i> , 2018, 124, 1856-1858. | 2.0 | 2 |
| 246 | Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829. | 0.5 | 2 |
| 247 | Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.. <i>Journal of Clinical Oncology</i> , 2021, 39, 35-35. | 0.8 | 2 |
| 248 | Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models. <i>FASEB Journal</i> , 2013, 27, lb572. | 0.2 | 2 |
| 249 | Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6527-6527. | 0.8 | 2 |
| 250 | HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2017, 35, 235-235. | 0.8 | 2 |
| 251 | Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16207-e16207. | 0.8 | 2 |
| 252 | Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 560-560. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 253 | Anti-angiogenic effects of curcumin and its novel analogs EF31 and UBS4109 in colorectal cancer. FASEB Journal, 2013, 27, 1b574. | 0.2 | 2 |
| 254 | Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.. Journal of Clinical Oncology, 2018, 36, e16262-e16262. | 0.8 | 2 |
| 255 | Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. Oncology & Hematology Review, 2019, 15, 27. | 0.2 | 2 |
| 256 | Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. Journal of Gastrointestinal Oncology, 2015, 6, 247-53. | 0.6 | 2 |
| 257 | Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas, 2021, 50, 1382-1391. | 0.5 | 2 |
| 258 | Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903. | 1.3 | 2 |
| 259 | Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. Oncologist, 2022, 27, 740-750. | 1.9 | 2 |
| 260 | A Phase I Study of Gemcitabine and Uracil-Ftorfar (UFT)/Leucovorin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 101-105. | 0.6 | 1 |
| 261 | Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. Case Reports in Oncology, 2009, 2, 220-228. | 0.3 | 1 |
| 262 | HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Surgical Oncology, 2020, 35, 460-465. | 0.8 | 1 |
| 263 | Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treatment and Research Communications, 2021, 27, 100329. | 0.7 | 1 |
| 264 | Survival Outcomes of Acinar Cell Pancreatic Cancer. Pancreas, 2021, 50, 529-536. | 0.5 | 1 |
| 265 | Impact of socioeconomic status (SES) on colorectal cancer patient survival: An analysis of 890,867 patients in the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 19-19. | 0.8 | 1 |
| 266 | Abstract 5816: Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy. Cancer Research, 2018, 78, 5816-5816. | 0.4 | 1 |
| 267 | Abstract 4074: Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer. , 2019, , . | | 1 |
| 268 | Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 6613-6613. | 0.8 | 1 |
| 269 | Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. Journal of Clinical Oncology, 2015, 33, 368-368. | 0.8 | 1 |
| 270 | Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 658-658. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 271 | Uridine triacetate as a life-saving antidote to capecitabine toxicity.. Journal of Clinical Oncology, 2016, 34, e21612-e21612. | 0.8 | 1 |
| 272 | Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.. Journal of Clinical Oncology, 2016, 34, 655-655. | 0.8 | 1 |
| 273 | Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 4125-4125. | 0.8 | 1 |
| 274 | Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs).. Journal of Clinical Oncology, 2018, 36, 421-421. | 0.8 | 1 |
| 275 | Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients.. Journal of Clinical Oncology, 2014, 32, 9626-9626. | 0.8 | 1 |
| 276 | Abstract C26: Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents. , 2014, , . | | 1 |
| 277 | A risk score to predict in-hospital mortality in patients with pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15256-e15256. | 0.8 | 1 |
| 278 | A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.. Journal of Clinical Oncology, 2016, 34, 230-230. | 0.8 | 1 |
| 279 | Racial disparities in treatment and outcomes of colorectal cancer in young adults.. Journal of Clinical Oncology, 2017, 35, 6559-6559. | 0.8 | 1 |
| 280 | A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.. Journal of Clinical Oncology, 2018, 36, TPS4155-TPS4155. | 0.8 | 1 |
| 281 | Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 435-435. | 0.8 | 1 |
| 282 | Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).. Journal of Clinical Oncology, 2019, 37, e15693-e15693. | 0.8 | 1 |
| 283 | Abstract 1205: Targeting vasoactive intestinal peptide signaling to enhance pancreatic cancer responsiveness to immunotherapy. , 2019, , . | | 1 |
| 284 | Abstract B59: IL-6 regulates CTLA4 expression on CD4+ T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma. , 2019, , . | | 1 |
| 285 | Immunotherapy in Pancreatic Cancer. Digestive Disease Interventions, 2020, 04, 351-357. | 0.3 | 1 |
| 286 | Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, TPS626-TPS626. | 0.8 | 1 |
| 287 | Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. Breast Cancer Research and Treatment, 2004, 83, 189-189. | 1.1 | 0 |
| 288 | Ritonavir mediated protection of retinoblastoma-E2F-1 complex at G1 phase of cell cycle in pancreatic cancer cell lines. Journal of the American College of Surgeons, 2008, 207, S97. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 289 | Tools to optimize the functionality of a leukemia clinical trial team. <i>Leukemia and Lymphoma</i> , 2013, 54, 110-116. | 0.6 | 0 |
| 290 | Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 477-486. | 1.0 | 0 |
| 291 | Nuclear Hypoxia-Inducible Factor 1 Alpha is a Predictor of Distant Failure in Patients With Resected Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S49. | 0.4 | 0 |
| 292 | Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354. | 0.6 | 0 |
| 293 | Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3842-3843. | 0.8 | 0 |
| 294 | Long-term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. <i>American Journal of Gastroenterology</i> , 2016, 111, S753-S754. | 0.2 | 0 |
| 295 | Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 673-674. | 0.6 | 0 |
| 296 | Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 89-89. | 0.8 | 0 |
| 297 | Impact of primary tumor size/horizontal extent on survival in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 125-125. | 0.8 | 0 |
| 298 | Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16259-e16259. | 0.8 | 0 |
| 299 | Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16085-e16085. | 0.8 | 0 |
| 300 | An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 206-206. | 0.8 | 0 |
| 301 | Abstract 2872: Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer. , 2012, , . | | 0 |
| 302 | Abstract 2326: Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer. , 2012, , . | | 0 |
| 303 | Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14512-e14512. | 0.8 | 0 |
| 304 | Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University.. <i>Journal of Clinical Oncology</i> , 2013, 31, 326-326. | 0.8 | 0 |
| 305 | Abstract LB-168: A pilot clinical trial of chromodomain-helicase-DNA-binding protein 7 (CHD7) expression as a prognostic and predictive biomarker in patients with early-stage pancreatic adenocarcinoma.. , 2013, , . | | 0 |
| 306 | Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15140-e15140. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 307 | Survival outcome of ampullary and duodenal adenocarcinomas.. Journal of Clinical Oncology, 2013, 31, e14579-e14579. | 0.8 | 0 |
| 308 | Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract.. Journal of Clinical Oncology, 2013, 31, e14612-e14612. | 0.8 | 0 |
| 309 | Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center.. Journal of Clinical Oncology, 2014, 32, 342-342. | 0.8 | 0 |
| 310 | Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.. Journal of Clinical Oncology, 2014, 32, 528-528. | 0.8 | 0 |
| 311 | Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT.. Journal of Clinical Oncology, 2014, 32, 276-276. | 0.8 | 0 |
| 312 | Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center.. Journal of Clinical Oncology, 2014, 32, 308-308. | 0.8 | 0 |
| 313 | Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6502-6502. | 0.8 | 0 |
| 314 | Abstract 4221: HSP90 as a therapeutic target in colorectal cancer. , 2014, , . | | 0 |
| 315 | Abstract 4216: Combination of anti-cancer small molecule tolfenamic acid and curcumin or curcumin analog EF31 effectively inhibits pancreatic cancer cell growth. , 2014, , . | | 0 |
| 316 | Abstract 1308: Functional inhibition of HSP90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. , 2014, , . | | 0 |
| 317 | The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.. Journal of Clinical Oncology, 2015, 33, 247-247. | 0.8 | 0 |
| 318 | Prognostic value of gender in hospitalized pancreatic patients.. Journal of Clinical Oncology, 2015, 33, 256-256. | 0.8 | 0 |
| 319 | Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases.. Journal of Clinical Oncology, 2015, 33, 4092-4092. | 0.8 | 0 |
| 320 | Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.. Journal of Clinical Oncology, 2015, 33, e17722-e17722. | 0.8 | 0 |
| 321 | Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States.. Journal of Clinical Oncology, 2015, 33, e15112-e15112. | 0.8 | 0 |
| 322 | Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.. Journal of Clinical Oncology, 2015, 33, e15260-e15260. | 0.8 | 0 |
| 323 | Abstract 2544: Combination of anti-cancer small molecule tolfenamic acid and curcumin effectively inhibits colon cancer cell growth. , 2015, , . | | 0 |
| 324 | Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors. , 2015, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 325 | Abstract 3778: Inhibition of NF- κ B translocation induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. , 2015, , . | | 0 |
| 326 | Abstract 699: PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results. , 2015, , . | | 0 |
| 327 | Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.. Journal of Clinical Oncology, 2016, 34, e21689-e21689. | 0.8 | 0 |
| 328 | Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.. Journal of Clinical Oncology, 2016, 34, e15541-e15541. | 0.8 | 0 |
| 329 | Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.. Journal of Clinical Oncology, 2016, 34, e21675-e21675. | 0.8 | 0 |
| 330 | Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 4045-4045. | 0.8 | 0 |
| 331 | Abstract 4818: Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF- κ B translocation to nucleus. , 2016, , . | | 0 |
| 332 | Abstract 4416: Combination of HSP90 and proteasome inhibitor is effective in pancreatic cancer. , 2016, , . | | 0 |
| 333 | Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.. Journal of Clinical Oncology, 2017, 35, 2552-2552. | 0.8 | 0 |
| 334 | Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, e18069-e18069. | 0.8 | 0 |
| 335 | Enrollment into molecular selection trials and impact on patient disposition.. Journal of Clinical Oncology, 2017, 35, e14035-e14035. | 0.8 | 0 |
| 336 | Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.. Journal of Clinical Oncology, 2017, 35, e15039-e15039. | 0.8 | 0 |
| 337 | Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4103-4103. | 0.8 | 0 |
| 338 | Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. Journal of Clinical Oncology, 2017, 35, e15607-e15607. | 0.8 | 0 |
| 339 | Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233. | | 0 |
| 340 | Resection of pancreatic cancer following induction chemotherapy.. Journal of Clinical Oncology, 2018, 36, 406-406. | 0.8 | 0 |
| 341 | STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?. Journal of Clinical Oncology, 2018, 36, 340-340. | 0.8 | 0 |
| 342 | Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.. Journal of Clinical Oncology, 2018, 36, 3604-3604. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 343 | Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.. Journal of Clinical Oncology, 2018, 36, 4026-4026. | 0.8 | 0 |
| 344 | Retrospective study of the safety of administering pegfilgrastim on the same day of 5- Fluorouracil pump disconnect.. Journal of Clinical Oncology, 2018, 36, e16190-e16190. | 0.8 | 0 |
| 345 | Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. Journal of Clinical Oncology, 2018, 36, e15022-e15022. | 0.8 | 0 |
| 346 | Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma. , 2018, , . | | 0 |
| 347 | Abstract 2607: Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO). , 2018, , . | | 0 |
| 348 | Small Bowel and Appendix Cancers. , 2019, , 97-107. | | 0 |
| 349 | Abstract B176: Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients. , 2019, , . | | 0 |
| 350 | Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn G14-198.. Journal of Clinical Oncology, 2019, 37, TPS475-TPS475. | 0.8 | 0 |
| 351 | Blood-based next-generation sequencing analysis of neuroendocrine tumors.. Journal of Clinical Oncology, 2019, 37, 4110-4110. | 0.8 | 0 |
| 352 | Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.. Journal of Clinical Oncology, 2019, 37, e15029-e15029. | 0.8 | 0 |
| 353 | Perioperative therapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e18231-e18231. | 0.8 | 0 |
| 354 | Personalized T cell therapy for metastatic colon cancer.. Journal of Clinical Oncology, 2019, 37, e15183-e15183. | 0.8 | 0 |
| 355 | Abstract 713: BBI-608 modulates DNA repair pathways, induces apoptosis and impacts response to 5-Fluorouracil and ionizing radiation in pancreatic cancer cells. , 2019, , . | | 0 |
| 356 | Abstract 205: BBI-608 enhances the activity of chemoradiotherapy in colorectal cancer pre-clinical models. , 2019, , . | | 0 |
| 357 | Abstract 3398: Interaction of STAT proteins with genistein: A computational analysis. , 2019, , . | | 0 |
| 358 | Abstract 4074: Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer. , 2019, , . | | 0 |
| 359 | Abstract A55: Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms. , 2019, , . | | 0 |
| 360 | Abstract 5571: Turning up the heat on pancreatic ductal adenocarcinoma via inhibiting vasoactive intestinal peptide signaling. , 2020, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 361 | Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?. Journal of Clinical Oncology, 2020, 38, 796-796. | 0.8 | 0 |
| 362 | 330â€¦Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies. , 2020, , . | | 0 |
| 363 | 819â€¦Targeting vasoactive intestinal peptide receptor signaling: a novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma. , 2020, , . | | 0 |
| 364 | A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. Journal of Clinical Oncology, 2022, 40, 563-563. | 0.8 | 0 |
| 365 | Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.. Journal of Clinical Oncology, 2022, 40, 194-194. | 0.8 | 0 |
| 366 | Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 4-4. | 0.8 | 0 |
| 367 | Abstract 3621: Targeted hyaluronic acid nanoparticles improve treatment response in pancreatic cancer. , 2019, , . | | 0 |
| 368 | Abstract 3967: Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX + stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment. , 2019, , . | | 0 |
| 369 | Abstract 2561: DNA-PKCS deacetylation by SIRT2 promotes DNA double-strand break repair by non-homologous end joining. , 2019, , . | | 0 |
| 370 | Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 4118-4118. | 0.8 | 0 |